This technology uses a gentle electrical current to deliver antifibrotic drugs like collagenase directly into fibrotic tissues, such as the bladder wall, enabling noninvasive, targeted treatment of fibrosis and improving tissue function without surgery.
Background: Fibrosis of the bladder wall, particularly in the context of neurogenic bladder, represents a significant clinical challenge in urology. Neurogenic bladder, often resulting from conditions such as spinal cord injury or spina bifida, leads to chronic dysfunction of bladder emptying and storage. Over time, repeated overdistention, infection, and inflammation can trigger excessive collagen deposition within the bladder wall, resulting in fibrosis. This pathological remodeling reduces bladder compliance, raises intravesical pressures, and increases the risk of incontinence, vesicoureteral reflux, and even kidney damage. The need for effective therapies is acute, as progressive fibrosis can lead to irreversible loss of bladder function and severe complications, impacting quality of life and long-term health outcomes. Current approaches to managing bladder fibrosis are limited and largely inadequate. There are no approved pharmacologic treatments capable of reversing established fibrosis or restoring normal tissue compliance. Standard medical management, such as antispasmodics and catheter drainage, only addresses symptoms without targeting the underlying fibrotic process. When conservative measures fail, patients often require invasive procedures like Botox injections or surgical bladder augmentation, both of which carry significant morbidity and do not directly address the excessive collagen buildup. Topical instillation of drugs is ineffective due to the impermeability of the urothelium, while systemic delivery of antifibrotic agents is hampered by poor tissue targeting and potential toxicity. As a result, there is a critical unmet need for a safe, effective, and targeted method to deliver therapeutic agents directly into fibrotic bladder tissue to halt or reverse disease progression.
Technology Overview: This technology is a noninvasive, targeted drug delivery system designed to treat fibrotic diseases, with a primary focus on bladder wall fibrosis associated with neurogenic bladder. It employs Electromotive Drug Administration (EMDA) to deliver therapeutic macromolecules directly into fibrotic tissues. The system works by applying a low-intensity electrical current through an intravesical catheter equipped with an active electrode, while a return electrode is placed on the abdominal skin. This electrical gradient increases urothelial permeability and actively drives charged therapeutic agents through the bladder wall, enabling deep tissue penetration that passive delivery methods cannot achieve. The approach allows for precise, localized degradation of pathological collagen buildup, restoring tissue compliance and function while minimizing systemic exposure. The platform is adaptable for co-administration of other antifibrotic agents, and can be paired with adjunct modalities such as ultrasound, further enhancing its therapeutic potential. What differentiates this technology is its ability to overcome the natural barriers that have historically limited the effectiveness of pharmacologic treatments for fibrosis in mucosal-lined organs. Unlike current options, which are largely invasive, this system provides a non-surgical, focal therapy that directly targets and remodels fibrotic tissue. Its use of EMDA for collagenase delivery is a novel application, leveraging clinically validated infrastructure to enable safe, controlled, and repeatable administration of large macromolecules. The platform’s flexibility allows for combination therapies and adaptation to a range of fibrotic conditions beyond the bladder, including urethral stricture, Peyronie’s disease, and even pulmonary or post-surgical fibrosis. This versatility, combined with its noninvasive nature and compatibility with existing clinical systems, positions the technology as a significant advancement with broad clinical and commercial impact.
https://suny.technologypublisher.com/files/sites/adobestock_1728653231.jpeg Photo for reference only, not a depiction of the invention.
Advantages: • Enables noninvasive, targeted delivery of collagenase and antifibrotic agents directly into fibrotic bladder tissue, overcoming urothelial barriers. • Restores bladder compliance and function by degrading pathological collagen buildup, addressing a currently untreatable condition. • Minimizes systemic exposure and off-target effects through localized, controlled drug administration. • Adaptable for combination therapies with secondary antifibrotic agents and adjunct modalities like ultrasound or shockwave therapy. • Uses safe, clinically validated electrical parameters and delivery infrastructure, facilitating clinical adoption. • Extensible to other fibrotic urogenital disorders and potentially to fibrosis in other mucosal-lined tissues. • Offers a non-surgical alternative to invasive procedures, reducing patient morbidity and healthcare costs. • Supports monitoring of therapeutic response via integrated biomarkers for optimized treatment.
Applications: • Bladder fibrosis treatment • Urethral stricture therapy • Peyronie’s disease intervention • Post-surgical adhesion prevention • Localized gastrointestinal fibrosis therapy
Intellectual Property Summary: Patent Pending
Stage of Development : Inquire for more information
Licensing Status: This technology is available for licensing.